Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7791075 | 1.00 | MPI (0.30) | MPI | |
| SCHEMBL29389821 | 0.86 | — | — | |
| SCHEMBL22748759 | 0.86 | — | — | |
| SCHEMBL30437675 | 0.86 | — | — | |
| SCHEMBL7154726 | 0.86 | — | — | |
| SCHEMBL29944830 | 0.86 | — | — | |
| SCHEMBL182612 | 0.86 | — | — | |
| SCHEMBL7151615 | 0.86 | — | — | |
| SCHEMBL7147900 | 0.86 | — | — | |
| SCHEMBL1406099 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0485577-B1 | IMMUNOSTIMULANT DRUG BASED ON POLAR GLYCOPEPTIDOLIPIDS OF MYCOBACTERIUM CHELONAE | NEWAY TSEHAY (FR) | 1995-08-30 | — | — | EP | claimed |
| US-5336666-A | Immunostimulant drug based on polar glyopeptidolipids of mycobacterium chelonae | NEWAY TSEHAY (FR) | 1994-08-09 | — | — | US | claimed |
| EP-0485577-A1 | IMMUNOSTIMULANT DRUG BASED ON POLAR GLYCOPEPTIDOLIPIDS OF MYCOBACTERIUM CHELONAE. | NEWAY TSEHAY (FR) | 1992-05-20 | — | — | EP | claimed |
| WO-1991018617-A1 | IMMUNOSTIMULANT DRUG BASED ON POLAR GLYCOPEPTIDOLIPIDS OF MYCOBACTERIUM CHELONAE | NEWAY TSEHAY (FR) | 1991-12-12 | — | — | WO | claimed |
| EP-3803400-B1 | IN VITRO METHOD FOR THE DIAGNOSIS OR DETECTION OF NON-TUBERCULOUS MYCOBACTERIA | FUNDACIO INST DINVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2023-08-09 | — | — | EP | disclosed |
| EP-3221337-B1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2021-08-04 | — | — | EP | disclosed |
| US-20210139540-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2021-05-13 | — | — | US | disclosed |
| EP-3803400-A1 | IN VITRO METHOD FOR THE DIAGNOSIS OR DETECTION OF NON-TUBERCULOUS MYCOBACTERIA | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES) | 2021-04-14 | — | — | EP | disclosed |
| US-10781235-B2 | Multivalent ligand-lipid constructs | BOVIN NICOLAI VLADIMIROVICH (RU) | 2020-09-22 | — | — | US | disclosed |
| US-20200048309-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2020-02-13 | — | — | US | disclosed |
| WO-2019234196-A1 | IN VITRO METHOD FOR THE DIAGNOSIS OR DETECTION OF NON-TUBERCULOUS MYCOBACTERIA | FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2019-12-12 | — | — | WO | disclosed |
| EP-2343285-B1 | Peptoid compounds useful as antibiotics | UNIV WOLLONGONG (AU) | 2015-02-25 | — | — | EP | disclosed |
| WO-2002086067-A2 | MYCOBACTERIAL SULFATION PATHWAY PROTEINS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1227839-A2 | LIVE BACTERIAL VACCINES AGAINST ESCHERICHIA COLI O157:H7 | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034190-A2 | LIVE BACTERIAL VACCINES AGAINST ESCHERICHIA COLI O157:H7 | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2001-05-17 | — | — | WO | disclosed |
| EP-0485577-B1 | IMMUNOSTIMULANT DRUG BASED ON POLAR GLYCOPEPTIDOLIPIDS OF MYCOBACTERIUM CHELONAE | NEWAY TSEHAY (FR) | 1995-08-30 | — | — | EP | disclosed |
| US-5336666-A | Immunostimulant drug based on polar glyopeptidolipids of mycobacterium chelonae | NEWAY TSEHAY (FR) | 1994-08-09 | — | — | US | disclosed |
| EP-0485577-A1 | IMMUNOSTIMULANT DRUG BASED ON POLAR GLYCOPEPTIDOLIPIDS OF MYCOBACTERIUM CHELONAE. | NEWAY TSEHAY (FR) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991018617-A1 | IMMUNOSTIMULANT DRUG BASED ON POLAR GLYCOPEPTIDOLIPIDS OF MYCOBACTERIUM CHELONAE | NEWAY TSEHAY (FR) | 1991-12-12 | — | — | WO | disclosed |
| US-4205164-A | Antibiotic A201C, A201D and A201E | ELI LILLY AND COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048309-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | PHOSPHO1, MGLL, LPAR6 | MPI 359/4885 |
| US-20210139540-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | PHOSPHO1, MGLL, LPAR6 | MPI 359/4885 |
| US-10781235-B2 | Multivalent ligand-lipid constructs | PHOSPHO1, MGLL, LPAR6 | MPI 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.